FDA Approval Fuels Leveraged Commercialization Pivot
Celcuity's FDA approval of gedatolisib (REVTORPYK) marks a pivotal transition from clinical to commercial stage, but the company's financial position is severely strained. Operating losses have widened to -$66.1M in 2026Q2, and total debt surged to $754.4M, driving shareholders' equity negative at -$12.8M.
AlTi Global Inc. cut its holdings in shares of Celcuity, Inc. (NASDAQ: CELC) by 68.9% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,287 shares of the company's stock after selling 11,689 shares during the period. AlTi Global Inc.'s
ACT Capital Partners L.P. bought a new stake in shares of Celcuity, Inc. (NASDAQ: CELC) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 58,650 shares of the company's stock, valued at approximately $4,664,000. Celcuity accounts for about 3.0% of
MINNEAPOLIS, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review its supplemental New Drug Application (“sNDA”) for REVTORPYK™ (gedatolisib) for the treatment of patients with hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”), locally advanced or metastatic breast cancer (“ABC”) with a PIK3CA mutation, following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. The FDA assigned a Prescription Drug User Fee Act (“PDUFA”) goal date of June 25, 2027.
Celcuity Inc. ( CELC ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Jodi Sievers - Head of Investor Relations & Corporate Communications Brian Sullivan - Co-Founder, Chairman & CEO Vicky Hahne - Chief Financial Officer Conference Call Participants Maurice Raycroft - Jefferies LLC, Research Division Anupam Rama - JPMorgan Chase & Co, Research Division Tara Bancroft - TD Cowen, Research Division Michael Schmidt - Guggenheim Securities, LLC, Research Division Gil Blum - Needham & Company, LLC, Research Division Daniel Bronder - Cantor Fitzgerald & Co., Research Division Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Silvan Tuerkcan - Citizens JMP Securities, LLC, Research Division Oliver McCammon - LifeSci Capital, LLC, Research Division Kalpit Patel - Wolfe Research, LLC Presentation Operator Good afternoon, ladies and gentlemen, and welcome to the Celcuity Third Quarter 2026 Financial Results Call and Webcast. [Operator Instructions] This call is being recorded on Thursday, November 5, 2026.
No. Celcuity Inc. (CELC) reported a net loss of $256.0M over the trailing twelve months.
Dividend & Returns
What is CELC's return on equity?
Celcuity Inc. (CELC) had a return on equity (ROE) of -1522.5% over the trailing twelve months. A negative ROE means the company lost money over the period.
What is Celcuity Inc.'s free cash flow?
Celcuity Inc. (CELC) had negative free cash flow of $213.5M over the trailing twelve months.